NGNE Quote, Financials, Valuation and Earnings

Coherus Oncology, Inc. has a net margin of -1999.14% compared to Neurogene, Inc.'s net margin of -384.73%. Neurogene, Inc.'s return on equity of -33.3% beat Coherus Oncology, Inc.'s return on equity of --.

Neurogene, Inc. has a consensus price target of $59.00, signalling upside risk potential of 194.85%. On the other hand Coherus Oncology, Inc. has an analysts' consensus of $5.67 which suggests that it could grow by 326.07%. Given that Coherus Oncology, Inc. has higher upside potential than Neurogene, Inc., analysts believe Coherus Oncology, Inc. is more attractive than Neurogene, Inc..

Neurogene, Inc. has a beta of 1.624, which suggesting that the stock is 62.381% more volatile than S&P 500. In comparison Coherus Oncology, Inc. has a beta of 0.951, suggesting its less volatile than the S&P 500 by 4.926%.

Neurogene, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Coherus Oncology, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Neurogene, Inc. pays -- of its earnings as a dividend. Coherus Oncology, Inc. pays out -- of its earnings as a dividend.

Neurogene, Inc. quarterly revenues are --, which are smaller than Coherus Oncology, Inc. quarterly revenues of $11.6M. Neurogene, Inc.'s net income of -$21M is higher than Coherus Oncology, Inc.'s net income of -$44.5M. Notably, Neurogene, Inc.'s price-to-earnings ratio is -- while Coherus Oncology, Inc.'s PE ratio is 1.06x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Neurogene, Inc. is -- versus 1.84x for Coherus Oncology, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

CorMedix, Inc. has a net margin of -1999.14% compared to Neurogene, Inc.'s net margin of 49.9%. Neurogene, Inc.'s return on equity of -33.3% beat CorMedix, Inc.'s return on equity of 95.25%.

Neurogene, Inc. has a consensus price target of $59.00, signalling upside risk potential of 194.85%. On the other hand CorMedix, Inc. has an analysts' consensus of $19.00 which suggests that it could grow by 51.64%. Given that Neurogene, Inc. has higher upside potential than CorMedix, Inc., analysts believe Neurogene, Inc. is more attractive than CorMedix, Inc..

Neurogene, Inc. has a beta of 1.624, which suggesting that the stock is 62.381% more volatile than S&P 500. In comparison CorMedix, Inc. has a beta of 1.322, suggesting its more volatile than the S&P 500 by 32.155%.

Neurogene, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CorMedix, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Neurogene, Inc. pays -- of its earnings as a dividend. CorMedix, Inc. pays out -- of its earnings as a dividend.

Neurogene, Inc. quarterly revenues are --, which are smaller than CorMedix, Inc. quarterly revenues of $104.3M. Neurogene, Inc.'s net income of -$21M is lower than CorMedix, Inc.'s net income of $108.6M. Notably, Neurogene, Inc.'s price-to-earnings ratio is -- while CorMedix, Inc.'s PE ratio is 6.10x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Neurogene, Inc. is -- versus 4.22x for CorMedix, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Ocugen, Inc. has a net margin of -1999.14% compared to Neurogene, Inc.'s net margin of -1144.46%. Neurogene, Inc.'s return on equity of -33.3% beat Ocugen, Inc.'s return on equity of -345.08%.

Neurogene, Inc. has a consensus price target of $59.00, signalling upside risk potential of 194.85%. On the other hand Ocugen, Inc. has an analysts' consensus of $9.00 which suggests that it could grow by 538.3%. Given that Ocugen, Inc. has higher upside potential than Neurogene, Inc., analysts believe Ocugen, Inc. is more attractive than Neurogene, Inc..

Neurogene, Inc. has a beta of 1.624, which suggesting that the stock is 62.381% more volatile than S&P 500. In comparison Ocugen, Inc. has a beta of 4.540, suggesting its more volatile than the S&P 500 by 354.007%.

Neurogene, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ocugen, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Neurogene, Inc. pays -- of its earnings as a dividend. Ocugen, Inc. pays out -- of its earnings as a dividend.

Neurogene, Inc. quarterly revenues are --, which are smaller than Ocugen, Inc. quarterly revenues of $1.8M. Neurogene, Inc.'s net income of -$21M is lower than Ocugen, Inc.'s net income of -$20.1M. Notably, Neurogene, Inc.'s price-to-earnings ratio is -- while Ocugen, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Neurogene, Inc. is -- versus 77.39x for Ocugen, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Verastem, Inc. has a net margin of -1999.14% compared to Neurogene, Inc.'s net margin of -876.34%. Neurogene, Inc.'s return on equity of -33.3% beat Verastem, Inc.'s return on equity of -1773.4%.

Neurogene, Inc. has a consensus price target of $59.00, signalling upside risk potential of 194.85%. On the other hand Verastem, Inc. has an analysts' consensus of $16.00 which suggests that it could grow by 98.51%. Given that Neurogene, Inc. has higher upside potential than Verastem, Inc., analysts believe Neurogene, Inc. is more attractive than Verastem, Inc..

Neurogene, Inc. has a beta of 1.624, which suggesting that the stock is 62.381% more volatile than S&P 500. In comparison Verastem, Inc. has a beta of 0.412, suggesting its less volatile than the S&P 500 by 58.798%.

Neurogene, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Verastem, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Neurogene, Inc. pays -- of its earnings as a dividend. Verastem, Inc. pays out -- of its earnings as a dividend.

Neurogene, Inc. quarterly revenues are --, which are smaller than Verastem, Inc. quarterly revenues of $11.2M. Neurogene, Inc.'s net income of -$21M is higher than Verastem, Inc.'s net income of -$98.5M. Notably, Neurogene, Inc.'s price-to-earnings ratio is -- while Verastem, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Neurogene, Inc. is -- versus 37.66x for Verastem, Inc.. Usually stocks with elevated PS ratios are considered overvalued.